SCHEMBL2845355

SCHEMBL2845355

COc1ccccc1NC(=O)C(Cl)(Cl)c1nnnn1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 4/20 0.48
MAPT P10636 4/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
CCR6 P51684 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
TSHR P16473 2/20 0.48
ADORA3 P0DMS8 1/20 0.46
RAB9A P51151 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 1/20 0.45
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2850071 0.89 MEN1 (0.47) SMN1; SMN2ALDH1A1MAPTTSHRRAB9A
SCHEMBL2853837 0.81 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1MAPTHPGDHTT
SCHEMBL14498665 0.69 RAB9A (0.57) SMN1; SMN2ALDH1A1MAPTHPGDTSHR
SCHEMBL1030263 0.69 LMNA (0.74) SMN1; SMN2ALDH1A1MAPTHTTRAB9A
SCHEMBL4407371 0.67 ALDH1A1 (0.79) SMN1; SMN2ALDH1A1MAPTHPGDHTT
SCHEMBL2006114 0.67 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MAPTHPGDHTT
SCHEMBL24210095 0.67 TSHR (0.85) SMN1; SMN2ALDH1A1MAPTTSHRPOLB
SCHEMBL2226280 0.66 PDK1 (0.72) SMN1; SMN2ALDH1A1MAPTHTTL3MBTL1
SCHEMBL6348512 0.66 PDK1 (0.72) SMN1; SMN2ALDH1A1MAPTHTTRAB9A
SCHEMBL2093161 0.66 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1MAPTHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130509-A1 NOVEL ANTIBIOTICS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWE- TENSCHAPPELIJK ONDERZOEK TNO (NL) 2010-05-27 US claimed
EP-1978021-A1 Novel antibiotics Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) 2008-10-08 EP claimed
US-20100130509-A1 NOVEL ANTIBIOTICS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWE- TENSCHAPPELIJK ONDERZOEK TNO (NL) 2010-05-27 US disclosed
EP-1978021-A1 Novel antibiotics Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) 2008-10-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130509-A1 NOVEL ANTIBIOTICS TMEM165, LAS1L, RPS2 SMN1; SMN2 4435/4885ALDH1A1 4431/4885MAPT 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.